September 11th 2025
Oxford’s Prof Katrina Lythgoe and Mahan Ghafari, DPhil, report ONS-CIS data on 576 persistent UK infections with rapid within-host evolution and rare transmission after one month.
September 10th 2025
William Hanage, PhD, discusses viral evolution, transmission risk, and clinical implications for immunocompromised patients.
September 3rd 2025
Single-center randomized trial shows lower infection rates and extended time to SARS-CoV-2 infection, though larger studies are needed to confirm findings.
September 2nd 2025
Supported by phase 3 SCORPIO-PEP trial data, ensitrelvir could become the first oral therapy to prevent COVID-19 following exposure, with an FDA decision due June 16, 2026.
August 29th 2025
Spikevax and mNEXSPIKE authorized for older adults and high-risk individuals; experts emphasize protection against severe COVID-19 outcomes.
ACE Inhibitors, ARBs Do Not Worsen COVID-19 Risk
May 29th 2020Early links between heart disease and diabetes and coronavirus severity caused some to fear that the 2 classes of medication might worsen outcomes during the pandemic. A systematic review finds little evidence to back those fears.
Read More
Helen W. Boucher, MD: Why We Need a Transparent Distribution Process for Remdesivir
May 26th 2020Helen W. Boucher, MD, FACP, FIDSA, discusses the need for a transparent distribution process for remdesivir, plus COVID disparities, secondary infections, and what “the new normal” of health care looks like.
Watch
259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831